High dose cytarabine (HiDAC) with amsacrine (AMSA) for relapsed and refractory adult lymphoblastic leukemia (ALL): Ongoing single institution experience

被引：0
|
作者：
Monahan, BP
Dahut, WL
机构：
[1] NATL NAVAL MED CTR, DIV HEMATOL, BETHESDA, MD USA
[2] NATL NAVAL MED CTR, DIV MED ONCOL, BETHESDA, MD USA
来源：
BLOOD | 1995年 / 86卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3072 / 3072
页数：1
相关论文
共 50 条
  • [21] Dose Optimization of Inotuzumab Ozogamicin in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
    Deangelo, Daniel J.
    Chen, Ying
    Cassaday, Ryan D.
    Hibma, Jennifer
    Yang, Derek Z.
    Garrett, May
    Zhang, Fan
    Dimitrov, Svetoslav H.
    Vandendries, Erik
    Kantarjian, Hagop M.
    BLOOD, 2024, 144 : 732 - 733
  • [22] Fludarabine, amsacrine, high-dose cytarabine and total body irridation followed by allogeneic stem cell transplantation for the treatment of high risk or relapsed acute lymphoblastic leukemia
    Zohren, Fabian
    Graef, Thorsten
    Bruns, Ingmar
    Czibere, Akos
    Roland, Fenk
    Rainer, Haas
    Guido, Kobbe
    BLOOD, 2007, 110 (11) : 352B - 353B
  • [23] HIGH-DOSE CYTARABINE (HD-ARA-C) IN REFRACTORY AND RELAPSED ADULT ACUTE MYELOGENOUS LEUKEMIA (AML)
    HOFELER, H
    ANDERS, CU
    POPESCU, O
    HOFFKEN, K
    SCHMIDT, CG
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 209 - 209
  • [24] Outcomes of six-dose high-dose cytarabine (HiDAC-6) as a salvage regimen for patients with relapsed/refractory acute myeloid leukemia (RR-AML).
    Veltri, Lauren Westfall
    Anders, Brandi
    Kanate, Abraham Sebastian
    Shillingburg, Alexandra
    Craig, Michael D.
    Cumpston, Aaron
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] A Single Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) for Treatment of Patients with Relapsed or Refractory Acute Myeloid Leukemia
    Christian, Sonia
    Patel, Pritesh
    Esen, Aysenur
    Khan, Irum
    Sweiss, Karen
    Ghanem, Fares
    Sequeira, Christopher A.
    Shergill, Ardaman
    Quigley, John G.
    BLOOD, 2017, 130
  • [26] Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience
    Gaut, Daria
    Burkenroad, Aaron
    Duong, Tuyen
    Feammelli, Jesse
    Sasine, Joshua
    Schiller, Gary
    LEUKEMIA RESEARCH, 2020, 90
  • [27] Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG)
    Sebastian Giebel
    Malgorzata Krawczyk-Kulis
    Maria Adamczyk-Cioch
    Beata Jakubas
    Grazyna Palynyczko
    Krzysztof Lewandowski
    Anna Dmoszynska
    Aleksander Skotnicki
    Katarzyna Nowak
    Jerzy Holowiecki
    Annals of Hematology, 2006, 85 : 717 - 722
  • [28] Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG)
    Giebel, Sebastian
    Krawczyk-Kulis, Malgorzata
    Adamczyk-Cioch, Maria
    Jakubas, Beata
    Palynyczko, Grazyna
    Lewandowski, Krzysztof
    Dmoszynska, Anna
    Skotnicki, Aleksander
    Nowak, Katarzyna
    Holowiecki, Jerzy
    ANNALS OF HEMATOLOGY, 2006, 85 (10) : 717 - 722
  • [29] MITOZANTRONE AND HIGH-DOSE CYTARABINE IN REFRACTORY ADULT ACUTE MYELOID-LEUKEMIA
    HIDDEMANN, W
    KREUTZMANN, H
    LUDWIG, WD
    AUL, HC
    DONHUIJSENANT, R
    LENGFELDER, E
    BUCHNER, T
    LANCET, 1985, 2 (8453): : 508 - 509
  • [30] A dose escalation and phase II study of gemtuzumab ozogamicin (GO) with high-dose cytarabine (HiDAC) for patients (Pts) with refractory or relapsed acute myeloid leukemia (AML): CALGB 19902.
    Stone, RM
    Moser, B
    Schulman, P
    Barrier, RC
    Kolitz, JE
    Allen, SL
    Stock, W
    Galinsky, IA
    Khoury, H
    Larson, RA
    BLOOD, 2004, 104 (11) : 249A - 249A
12345